Microencapsulation of PEGylated Adenovirus within PLGA Microspheres for Enhanced Stability and Gene Transfection Efficiency

PurposeGreen fluorescent protein (GFP) encoding adenovirus (ADV) was surface modified with polyethylene glycol (PEG) for microencapsulation within poly(lactic-co-glycolic acid) (PLGA) microspheres with the aim of improving stability and gene transfection activity.MethodsA series of PEGylated ADV (PEG-ADV) with different PEG seeding densities on the viral surface was prepared and the GFP expression efficiency of each PEG-ADV in the series determined. The physical stabilities of naked ADV and PEG-ADV were comparatively evaluated by exerting a high shear homogenization process or by exposure to low pH. Naked ADV or PEG-ADV was microencapsulated within PLGA microspheres using a water-in-oil-in-water (W/O/W) double emulsion and solvent evaporation method. In vitro cumulative ADV and PEG-ADV release profiles from PLGA microspheres were determined over a 10-day period. GFP transfection efficiencies into HeLa cells were quantified, and the relative extent of the immune response for ADV and PEG-ADV encapsulated within PLGA microspheres was analyzed using macrophage cells.ResultsThe physical stability of PEGylated ADV was greatly enhanced relative to that of naked ADV under the simulated W/O/W formulation conditions, such as exposure to an aqueous/organic interface during high shear-stressed homogenization. PEG-ADV was also more stable than ADV at low pH. ADV and PEG-AD were both released from PLGA microspheres similarly in a sustained fashion. However, when the ADV and PEG-ADV encapsulated microspheres transfected into HeLa cells, PEG-ADV microspheres demonstrated a higher GFP gene transfection efficiency than ADV microspheres. The PEG-ADV microspheres also exhibited a reduced extent of innate immune response for macrophage cells.ConclusionsPEGylated ADV could be more safely microencapsulated within PLGA microspheres than naked ADV due to their enhanced physical stability under the harsh formulation conditions and acidic microenvironmental conditions of the microsphere, thereby increasing gene transfection efficiency.

[1]  T. Park,et al.  Pegylation enhances protein stability during encapsulation in PLGA microspheres. , 2001, Journal of controlled release : official journal of the Controlled Release Society.

[2]  T. Park,et al.  Determinants of Release Rate of Tetanus Vaccine from Polyester Microspheres , 1993, Pharmaceutical Research.

[3]  D. Majhen,et al.  Adenoviral vectors--how to use them in cancer gene therapy? , 2006, Virus research.

[4]  J. Hennessey,et al.  Evaluation of accuracy and precision of adenovirus absorptivity at 260 nm under conditions of complete DNA disruption. , 2002, Virology.

[5]  Tae Gwan Park,et al.  Pegylated recombinant human epidermal growth factor (rhEGF) for sustained release from biodegradable PLGA microspheres. , 2002, Biomaterials.

[6]  D. Muruve,et al.  The innate immune response to adenovirus vectors. , 2004, Human gene therapy.

[7]  L. Medina-Kauwe.  Endocytosis of adenovirus and adenovirus capsid proteins. , 2003, Advanced drug delivery reviews.

[8]  M. Barry,et al.  Evaluation of polyethylene glycol modification of first-generation and helper-dependent adenoviral vectors to reduce innate immune responses. , 2005, Molecular therapy : the journal of the American Society of Gene Therapy.

[9]  Davidson,et al.  Extended release of adenovirus from polymer microspheres: potential use in gene therapy for brain tumors. , 1997, Advanced drug delivery reviews.

[10]  Xuan Cheng,et al.  PEGylated Adenoviruses for Gene Delivery to the Intestinal Epithelium by the Oral Route , 2003, Pharmaceutical Research.

[11]  M. Mizuno,et al.  Cationic liposomes conjugation to recombinant adenoviral vectors containing herpes simplex virus thymidine kinase gene followed by ganciclovir treatment reduces viral antigenicity and maintains antitumor activity in mouse experimental glioma models , 2002, Cancer Gene Therapy.

[12]  T. Park,et al.  Comparative study on sustained release of human growth hormone from semi-crystalline poly(L-lactic acid) and amorphous poly(D,L-lactic-co-glycolic acid) microspheres: morphological effect on protein release. , 2004, Journal of controlled release : official journal of the Controlled Release Society.

[13]  D. Lewis,et al.  PEGylated insulin in PLGA microparticles. In vivo and in vitro analysis. , 2005, Journal of controlled release : official journal of the Controlled Release Society.

[14]  B. Trapnell,et al.  Nonspecific inflammation inhibits adenovirus-mediated pulmonary gene transfer and expression independent of specific acquired immune responses. , 1998, Human gene therapy.

[15]  H. Merkle,et al.  Microencapsulation of DNA using poly(DL-lactide-co-glycolide): stability issues and release characteristics. , 1999, Journal of controlled release : official journal of the Controlled Release Society.

[16]  H. Mizuguchi,et al.  Targeted adenovirus vectors. , 2004, Human gene therapy.

[17]  C Russell Middaugh,et al.  Effect of pH and ionic strength on the physical stability of adenovirus type 5. , 2006, Journal of pharmaceutical sciences.

[18]  J. Wilson,et al.  Development of a rapid method for the PEGylation of adenoviruses with enhanced transduction and improved stability under harsh storage conditions. , 2000, Human gene therapy.

[19]  M. Herlyn,et al.  FGF2-Targeted adenovirus encoding platelet-derived growth factor-B enhances de novo tissue formation. , 2000, Molecular therapy : the journal of the American Society of Gene Therapy.

[20]  M. Rots,et al.  A novel strategy to modify adenovirus tropism and enhance transgene delivery to activated vascular endothelial cells in vitro and in vivo. , 2004, Human gene therapy.

[21]  Alan E. Smith,et al.  PEGylation of adenovirus with retention of infectivity and protection from neutralizing antibody in vitro and in vivo. , 1999, Human gene therapy.

[22]  G. Kwon,et al.  Poly(D,L-lactic-co-glycolic acid) microsphere delivery of adenovirus for vaccination. , 2007, Journal of pharmacy & pharmaceutical sciences : a publication of the Canadian Society for Pharmaceutical Sciences, Societe canadienne des sciences pharmaceutiques.

[23]  T. Park,et al.  Folate immobilized and PEGylated adenovirus for retargeting to tumor cells. , 2006, Bioconjugate chemistry.

[24]  M. Burton,et al.  In-vitro evaluation of ion-exchange microspheres for the sustained release of liposomal-adenoviral conjugates. , 2004, Journal of controlled release : official journal of the Controlled Release Society.

[25]  J. Wilson,et al.  Development of novel formulations that enhance adenoviral-mediated gene expression in the lung in vitro and in vivo. , 2001, Molecular therapy : the journal of the American Society of Gene Therapy.

[26]  Chung C. Hsu,et al.  Effect of high shear on proteins , 2000, Biotechnology and bioengineering.

[27]  B. Davidson,et al.  Poly (lactic-glycolic) acid copolymer encapsulation of recombinant adenovirus reduces immunogenicity in vivo , 1998, Gene Therapy.

[28]  T. Burke,et al.  The Acidic Microclimate in Poly(lactide-co-glycolide) Microspheres Stabilizes Camptothecins , 1999, Pharmaceutical Research.

[29]  M. Mccaman,et al.  Quantitation of adenovirus DNA and virus particles with the PicoGreen fluorescent Dye. , 1999, Analytical biochemistry.

[30]  M. Burton,et al.  A Microsphere-Liposome (Microplex) Vector for Targeted Gene Therapy of Cancer. II. In Vivo Biodistribution Study in a Solid Tumor Model , 2000, Drug delivery.

[31]  Alberto Smith,et al.  Glycoviruses: chemical glycosylation retargets adenoviral gene transfer. , 2005, Angewandte Chemie.

[32]  F. Mi,et al.  Chitin/PLGA blend microspheres as a biodegradable drug delivery system: a new delivery system for protein. , 2003, Biomaterials.

[33]  J. Maizel,et al.  The polypeptides of adenovirus. I. Evidence for multiple protein components in the virion and a comparison of types 2, 7A, and 12. , 1974, Virology.